Scientists have created a mosaic-8 nanoparticle vaccine that targets conserved regions across various coronaviruses to elicit broad antibody responses. Clinical trials for this candidate are scheduled to begin in 2025.

A comprehensive global study confirms the safety and efficacy of mRNA vaccine technology after billions of doses. Researchers are now exploring its potential to treat influenza, RSV, cancer, and autoimmune disorders.